市場調查報告書

哮喘和COPD治療藥物的全球市場:2020-2026

Global Asthma and COPD Drugs Market 2020-2026

出版商 Orion Market Research Pvt Ltd 商品編碼 949448
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
哮喘和COPD治療藥物的全球市場:2020-2026 Global Asthma and COPD Drugs Market 2020-2026
出版日期: 2020年05月21日內容資訊: 英文
簡介

在預測期內,全球哮喘和COPD治療藥物市場預計將以顯著的複合年增長率增長。市場增長是由於哮喘和COPD患者的數量增加以及哮喘和COPD治療劑的臨床試驗數量增加。人們生活方式的改變是呼吸系統疾病的主要原因。人們之間的吸煙,飲酒和不健康飲食行為正在增加,這是發展各種呼吸系統疾病的主要風險。根據美國COPD基金會的調查,導致COPD的三大原因是環境因素,吸煙和遺傳因素。 COPD主要發生在40歲以上吸煙的人群中。在美國,約90%的COPD患者有吸煙史。

本報告調查和分析了全球哮喘和COPD治療藥物市場,市場概況,影響市場增長的因素,市場規模和預測,按細分市場進行的市場分析,按地區/國家進行的市場分析以及競爭。我們提供有關情況的系統信息。

內容

第1章報告概述

第2章市場概述和討論

  • 調查範圍
  • 分析師見解和當前市場趨勢
  • 規則與規定

第3章競爭情況

  • 公司份額分析
  • 主要策略分析
  • 主要公司分析
    • 阿斯利康PLC
    • 勃林格殷格翰國際有限公司
    • Grifols,美國
    • 葛蘭素史克(GlaxoSmithKline)PLC 輝瑞公司

第4章市場決定因素

  • 主持人
  • 抑制因子
  • 機會

第5章市場細分

  • 按類型分列的全球哮喘和COPD治療市場
    • 哮喘
    • COPD
  • 按藥物類別劃分的全球哮喘和COPD治療市場
    • 抗炎藥
    • 伴隨藥物
    • 單克隆抗體
    • 支氣管擴張劑

第6章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 其他亞太地區
  • 其他地區

第7章公司簡介

  • Amgen Inc.
  • AptarGroup, Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Grifols, S.A.
  • Glenmark Pharmaceuticals
  • Merck & Co., Inc.
  • MediciNova, Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Respiratorius AB
  • Teva Pharmaceutical Industries Ltd.
  • Vectura Group plc
  • Verona Pharma plc
目錄
Product Code: OMR2021767

Global Asthma and COPD Drugs Market Size, Share & Trends Analysis Report by Disease Type(Asthma and COPD), By Application (Cardiology, Orthopedics, General Surgery &Anesthesia, Neurology Urology, Others) and Forecast 2020-2026

The global asthma and COPD drugs market is estimated to grow significantly during the forecast period. The growth of the market is attributed to the increasing number of patients with asthma and COPD coupled with growing clinical trials on asthma and COPD drugs. Changing lifestyle of the people is a major cause of respiratory diseases among people. Trend of smoking, drinking alcohol and ill eating activity are increasing among the people which is a major risk for the development of various respiratory related diseases. As per COPD Foundation of the US, top three causes of COPD are environmental factor, smoking and genetic factor. COPD is mostly occurred in the people of age above 40 and having a history of smoking. About 90% of the COPD patients in the US have smoking history. Therefore lifestyle changes further increases the number of cases of respiratory diseases that further contribute in the market growth.

The global asthma and COPD drugs market is segmented on the basis of disease type and drug class. Based on the disease type, the market is further classified into asthma and COPD. The asthma segment is projected to have a considerable share in the global market owing to the high number of cases of asthma across the globe. Based on the drug class, the global asthma and COPD drugs market is further segmented into anti-inflammatory drugs, combination drugs, monoclonal antibodies, bronchodilators. Based on geography, the global asthma and COPD drugs market is further segregated into North America, Europe, Asia-Pacific and the Rest of the World. Among, region North America projected to have a considerable share in the global asthma and COPD drugs market.

The companies which are contributing to the growth of the global asthma and COPD drugs market include AstraZeneca PLC, Boehringer Ingelheim International GmbH, Grifols, S.A., GlaxoSmithKline PLC, Pfizer Inc., and others. Product launch, merger, and acquisition, collaborations with government, and technological advancements through which market players are considerably contributing to the market growth to stay competitive in the market.

Research Methodology

The market study of the global asthma and COPD drugs market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for asthma and COPD drugs providers, end-user companies for overall market analysis, and competitive analysis. The report provides an in-depth analysis of pricing, market size, intended quality of the product preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models delivering insights into the market for better business decisions.

Market Segmentation

1. Global asthma and COPD drugs Market Research and Analysis by Disease Type

2. Global asthma and COPD drugs Market Research and Analysis by Drug Class

The Report Covers:

  • Comprehensive research methodology of the global asthma and COPD drugs market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global asthma and COPD drugs market.
  • Insights about market determinants which are stimulating the global asthma and COPD drugs market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. AstraZeneca PLC
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Boehringer Ingelheim International GmbH
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Grifols, S.A.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. GlaxoSmithKline PLC
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Pfizer Inc.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Asthma and COPD Drugs Market by Disease Type
    • 5.1.1. Asthma
    • 5.1.2. COPD
  • 5.2. Global Asthma and COPD Drugs Market by Drug class
    • 5.2.1. Anti-inflammatory Drugs
    • 5.2.2. Combination Drugs
    • 5.2.3. Monoclonal Antibodies
    • 5.2.4. Bronchodilators

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Amgen Inc.
  • 7.2. AptarGroup, Inc.
  • 7.3. AstraZeneca PLC
  • 7.4. Boehringer Ingelheim International GmbH
  • 7.5. Cipla Ltd.
  • 7.6. F. Hoffmann-La Roche Ltd.
  • 7.7. GlaxoSmithKline PLC
  • 7.8. Grifols, S.A.
  • 7.9. Glenmark Pharmaceuticals
  • 7.10. Merck & Co., Inc.
  • 7.11. MediciNova, Inc.
  • 7.12. Mylan N.V.
  • 7.13. Novartis AG
  • 7.14. Pfizer Inc.
  • 7.15. Respiratorius AB
  • 7.16. Teva Pharmaceutical Industries Ltd.
  • 7.17. Vectura Group plc
  • 7.18. Verona Pharma plc

LIST OF TABLES

  • 1. GLOBAL ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2019-2026 ($ MILLION)
  • 2. GLOBAL ASTHMA DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL COPD DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)

4. G

  • 5. GLOBAL ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
  • 6. GLOBAL ANTI-INFLAMMATORY DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 7. GLOBAL COMBINATION DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 8. GLOBAL MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 9. GLOBAL BRONCHODILATORS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 10. GLOBAL ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 11. NORTH AMERICAN ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 12. NORTH AMERICAN ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2019-2026 ($ MILLION)
  • 13. NORTH AMERICAN ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
  • 14. EUROPEAN ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 15. EUROPEAN ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2019-2026 ($ MILLION)
  • 16. EUROPEAN ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
  • 17. ASIA-PACIFIC ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 18. ASIA-PACIFIC ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2019-2026 ($ MILLION)
  • 19. ASIA-PACIFIC ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
  • 20. REST OF THE WORLD ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2019-2026 ($ MILLION)
  • 21. REST OF THE WORLD ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL ASTHMA AND COPD DRUGS MARKET SHARE BY DISEASE TYPE, 2019 VS 2026 (%)
  • 2. GLOBAL ASTHMA AND COPD DRUGS MARKET SHARE BY DRUG CLASS, 2019 VS 2026 (%)
  • 3. GLOBAL ASTHMA AND COPD DRUGS MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 4. US ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 5. CANADA ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. UK ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. FRANCE ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. GERMANY ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. ITALY ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. SPAIN ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. ROE ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. INDIA ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. CHINA ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. JAPAN ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 16. REST OF THE WORLD ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)